NEW YORK, Feb. 28, 2011 /PRNewswire/ -- NeoStem, Inc. (NYSE: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced today that Dr. Robin Smith, the Company's Chairman and CEO, will present on Tuesday, March 1, 2011 at the Wall Street Analyst Forum 22nd Annual Analyst Conference. The Conference will be held at the University Club at 1 West 54th Street, New York, New York. Dr. Smith will present as part of Track 2: "Biotechnology and Specialty Pharmaceuticals" from 9:50 AM to 10:30 AM.
In recapping its recent highlights, the Company will review multiple accomplishments. In January 2011, the Company acquired Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized cell therapy services and development company that, through its cGMP certified manufacturing facilities and team of professionals, facilitates the preclinical and clinical development and eventual commercialization of cellular therapies for clients in the United States and internationally. In November 2010, the Company raised $19 million from two concurrent offerings. These funds supported the closing of the PCT acquisition and are helping the Company in growing its revenue lines of businesses in the US and China. Also in 2010, NeoStem was named "Best Stem Cell Company, 2010" in The New Economy's Biotech Awards. Additionally, the Vatican's Pontifical Council has undertaken to commit $1 million to joint ventures with NeoStem and the Stem for Life Foundation, a not-for-profit entity NeoStem participated in founding, to expand research and raise awareness of adult stem cell therapies.
In 2010, the Company also began generating revenues from what it believes will be the beginning of a pipeline of stem cell-based regenerative medicine therapies, a key element of its growth strategy in both the United States and China, with a collaboration with Wendeng Hospital in China whereby patients are being offered the benefit of the latest technology from the US in the treatment of a range of orthopedic conditions. Additionally, the ongoing relocation of Suzhou Erye Pharmaceutical's new manufacturing facility continues to progress and should be completed in 2011 thereby significantly increasing capacity.
Dr. Robin Smith said, "NeoStem is proud of its recent accomplishments, from its groundbreaking partnership with the Vatican to its recognition by The New Economy as 'Best Stem Cell Company, 2010'. Now, with the acquisition of PCT, the new company shows even greater promise."
About NeoStem, Inc.NeoStem, Inc. is an international biopharmaceutical company with adult stem cell operations in the U.S., a network of adult stem cell therapeutic providers in China as well as a 51% ownership interest in a profitable Chinese generic pharmaceutical manufacturing company. NeoStem is focused on accelerating the development of proprietary cellular therapies and becoming a single source for collection, storage, manufacturing, therapeutic development and transportation of cells for cell based medicine and regenerative science globally. The Company also has licensed various cellular therapy technologies, including worldwide exclusive licenses to a wound healing technology and to VSEL™ Technology which uses very small embryonic-like stem cells, which are adult stem cells that have been shown to have several physical characteristics that are generally found in embryonic stem cells.
For more information, please visit: http://www.neostem.com.
About the Wall Street Analyst ForumThe WSAF has been the leading independent sponsor of over 80 analyst conferences in NYC, Boston & London since 1989. Over 2,500 corporations have participated ranging from Motorola, Inc., Mattel, Inc., General Electric, to Pfizer, Inc. Institutional investors from over 2000 money management firms have attended. Our conferences receive coverage in The WSJ, Barron's, CNBC, and Bloomberg.
For more information, please visit: http://www.analyst-conference.com.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability of PCT's business to complement NeoStem's adult stem cell operations and successful execution of the Company's strategy, as well as other advances in the Company's business, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, its Form S-4/A filed with the Securities and Exchange Commission on December 3, 2010 as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control. NeoStem may experience difficulties in integrating PCT's business and could fail to realize potential benefits of the merger. Acquisitions may entail numerous risks for NeoStem, including difficulties in assimilating acquired operations, technologies or products, including the loss of key employees from acquired businesses.For more information, please contact:NeoStem, Inc.Robin Smith, CEOPhone: +1-212-584-4174Email: firstname.lastname@example.org Web: http://www.neostem.com
|SOURCE NeoStem, Inc.|
Copyright©2010 PR Newswire.
All rights reserved